3-(Trimethylsilylethynyl)Pyridine 98.0%(GC)

Rifaximin is a semisynthetic analog of rifamycin with poor absorptivity. It selectively inhibits (E. coli B subtilis) bacterial DNA-dependent RNA polymerase by a mechanism similar to rifabutin subunit binding. It is effective against aerobic and anaerobic Gram-positive and Gram-negative bacteria. It is active against species ofStaphylococcusStreptococcusandEnterococcus.

For R&D use onlynot for drug household or other uses.

Rifaximin (trade namesRCIFAX Rifagut Xifaxan Zaxine) is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of travelers diarrhea irritable bowel syndrome and hepatic encephalopathy for which it received orphan drug status from the U.S. Food and Drug Administration in 1998.